An ultrasensitive and disposable electrochemical aptasensor for prostate-specific antigen (PSA) detection in real serum samples

Özyurt, Canan; Uludağ, İnci; Sezgintürk, Mustafa Kemal

doi:10.1007/s00216-022-04309-8

Cited by 11 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The review includes 115 studies and 67,479 patients . Year Study Reference Method LLD (ng/L) 2023 Ozyurt [23] ITO-PET 0.0074 Wu [27] Ag NP 0.001 2022 Cao [28] PtNP@Co2O4 NP 10 Wu [27] Ag NP 0.001 Cao [28] PtNP@Co2O4 NP 10…”

Section: Search For Studies and Analyses Of The Studiesmentioning

confidence: 99%

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

von Eyben,

Kairemo,

Kapp

2024

Biomedicines

View full text Add to dashboard Cite

Serum prostate-specific antigen (PSA) needs to be monitored with ultrasensitive PSA assays (uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is <0.5 µg/L for patients with prostate cancer (PCa) relapsing after a radical prostatectomy (RP). Our systematic review (SR) aimed to summarize uPSAs for patients with localized PCa. The SR was registered as InPLASY2023110084. We searched for studies on Google Scholar, PUBMED and reference lists of reviews and studies. We only included studies on uPSAs published in English and excluded studies of women, animals, sarcoidosis and reviews. Of the 115 included studies, 39 reported PSA assay methods and 76 reported clinical findings. Of 67,479 patients, 14,965 developed PSA recurrence (PSAR) and 2663 died. Extremely low PSA nadir and early developments of PSA separated PSAR-prone from non-PSAR-prone patients (cumulative p value 3.7 × 1012). RP patients with the lowest post-surgery PSA nadir and patients who had the lowest PSA at SRT had the fewest deaths. In conclusion, PSA for patients with localized PCa in the pre-PSAR phase of PCa is strongly associated with later PSAR and survival. A rising but still exceedingly low PSA at SRT predicts a good 5-year overall survival.

show abstract